<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933231</url>
  </required_header>
  <id_info>
    <org_study_id>FKC-014</org_study_id>
    <nct_id>NCT00933231</nct_id>
  </id_info>
  <brief_title>Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts</brief_title>
  <official_title>A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Canada, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre study examining the use of Advagraf-minimization strategy and/or the
      use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal
      allografts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of the following 4 treatment groups.:

        1. Standard dose Advagraf with angiotensin-converting enzyme inhibitor (ACEi)/angiotensin
           receptor blocker (ARB) antihypertensive therapy

        2. Standard dose Advagraf without ACEi/ARB antihypertensive therapy

        3. Low dose Advagraf with ACEi/ARB antihypertensive therapy

        4. Low dose Advagraf without ACEi/ARB antihypertensive therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2009</start_date>
  <completion_date type="Actual">April 3, 2018</completion_date>
  <primary_completion_date type="Actual">May 11, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with the Presence of Allograft Interstitial Fibrosis and Tubular Atrophy (IF/TA) as Assessed at a Central Pathology Lab</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression of IF/TA from Month 6 to Month 24</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to T-cell Banff Mediated Rejection as Assessed at a Central Pathology Lab</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Category of Banff 2007 Diagnostic Classification of Renal Allograft Pathology</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Humoral Rejections</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Acute Rejections</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Any Acute Rejection</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Banff 2007 Individual Sub-scores</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Banff 2007 sub-scores (AH = Arteriolar hyalinethickening score; AT = Tubulitis score; AV = Intimal arteritis score; AI = Interstitial inflammation score; AG = Glomerulitis score; CG = Glomerulopathy score; CI = Interstitial fibrosis score; CT = Tubularatrophy score; CV = Vascular fibrous intimal thickening score; MM = Mesangial matrix increase score; TI = Total interstitial inflammation score; PTC = Peritubulary capillaritis score) is measured on an ordinal scale of 0 - 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Chronic Allograft Damage Index</measure>
    <time_frame>Baseline and 6, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Circulating Anti-Donor Antibody</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Cellular Immune Response (ELISPOT)</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Renal Biomarkers</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function as Measured by Glomerular Filtration Rate (GFR)</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function as Measured by Serum Creatinine</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function as Measured by Ratio of Urine Protein and Creatinine Concentrations</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Item Short Form (SF-12) Health Survey: Physical Composite Score (PCS) and Mental Health Composite Score (MCS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The PCS and MCS are measured on a normalized 0-100 scale and computed using the corresponding subdomains from the SF-12 with 0 being the lowest level of health and 100 the highest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Transplant Recipient Opinions of Immunosuppressive Medications Questionnaire</measure>
    <time_frame>up to 24 months</time_frame>
    <description>This questionnaire consists of 11 questions regarding immunosuppressive medications, where questions 1-3 ask about your experiences and opinions of transplant anti-rejection medications, questions 4 and 11 ask to rate each medication on the scale of 1-10, with 1 meaning disagree completely and 10 meaning agree completely, and questions 5-10 ask which medication satisfies the question.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Polyomavirus Infection</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Tacrolimus Standard Dose with ACEi/ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a standard dose of tacrolimus with ACEi/ARB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus Standard Dose without ACEi/ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a standard dose of tacrolimus without ACEi/ARB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus Low Dose with ACEi/ARB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a low dose of tacrolimus with ACEi/ARB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus Low Dose without ACEi/ARB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a low dose of tacrolimus without ACEi/ARB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Standard dose, Oral</description>
    <arm_group_label>Tacrolimus Standard Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose without ACEi/ARB</arm_group_label>
    <other_name>Advagraf</other_name>
    <other_name>FK506XL</other_name>
    <other_name>Prolonged Release Tacrolimus</other_name>
    <other_name>Tacrolimus XL</other_name>
    <other_name>Extended Release Tacrolimus</other_name>
    <other_name>FK506E</other_name>
    <other_name>MR4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Low dose, Oral</description>
    <arm_group_label>Tacrolimus Low Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Low Dose without ACEi/ARB</arm_group_label>
    <other_name>Prolonged Release Tacrolimus</other_name>
    <other_name>FK506XL</other_name>
    <other_name>Extended Release Tacrolimus</other_name>
    <other_name>Tacrolimus XL</other_name>
    <other_name>FK506E</other_name>
    <other_name>MR4</other_name>
    <other_name>Advagraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Simulect</intervention_name>
    <description>IV</description>
    <arm_group_label>Tacrolimus Low Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Low Dose without ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose without ACEi/ARB</arm_group_label>
    <other_name>Basiliximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cellcept</intervention_name>
    <description>Oral</description>
    <arm_group_label>Tacrolimus Low Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Low Dose without ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose without ACEi/ARB</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>IV and Oral</description>
    <arm_group_label>Tacrolimus Low Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Low Dose without ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose without ACEi/ARB</arm_group_label>
    <other_name>Methylprednisolone</other_name>
    <other_name>prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Oral</description>
    <arm_group_label>Tacrolimus Low Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose with ACEi/ARB</arm_group_label>
    <other_name>Altace</other_name>
    <other_name>ACEi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Oral</description>
    <arm_group_label>Tacrolimus Low Dose with ACEi/ARB</arm_group_label>
    <arm_group_label>Tacrolimus Standard Dose with ACEi/ARB</arm_group_label>
    <other_name>Avapro</other_name>
    <other_name>ARB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is the recipient of a first or second deceased or living donor renal
             transplant (one kidney only)

          -  Subject must have at least one HLA-mismatch with the donor. HLA identical
             donor-recipient pairs are not eligible

          -  Subject understands either English or French

          -  If female and of child-bearing potential, subject has a negative pregnancy test and
             utilizes adequate contraceptive methods

        Exclusion Criteria:

          -  Presence of donor specific antibody

          -  Subject who is currently participating in a study with investigational drug, or who
             has received investigational drug within three months prior to randomization.
             Observational studies are acceptable

          -  Subject who has lost a previous graft for immunological reasons less than one year
             from transplant

          -  Subject is pregnant or breastfeeding

          -  Subject receives a kidney lacking pre-implantation biopsy

          -  Subject has significant disease (e.g. malignancy or uncontrolled infection) or
             disability (e.g. cognitive defect) which prevents understanding of, or adherence to
             the protocol

          -  Subject who in the opinion of the Investigator, require ACEi/ARB therapy
             post-transplant for any indication

          -  Subject who requires induction with Thymoglobulin, Campath, antithymocyte globulin
             (ATG), antilymphocyte globulin (ALG) or any biological induction agent other than
             basiliximab. Unplanned post-transplant use of these prohibited drugs for clinical
             indications post-transplant is allowed

          -  Subject has plans to become pregnant within 2 years post-transplant

          -  Subject who has a positive T-cell or B-cell crossmatch. Subjects with a weakly
             positive B-cell cross-match that tests negative following DTT reduction are acceptable

          -  Subject who has a requirement for maintenance immunosuppressant therapy with the
             exception of low dose steroid or mycophenolate mofetil (MMF). A subject who is on low
             dose tacrolimus maintenance therapy will be eligible provided the tacrolimus is
             withheld at least 1 week prior to transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Canada, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site CA133 Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA54 University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA141 Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA114 Capital District Health Authority- QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA150 St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA27 London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA165 St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA238 Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA172 Hôpital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA144 McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA116 Centre Hospitalier Universitaire de Sherbrooke- Hôpital Fleuirmont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA142 St. Paul's Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7V 0Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA64 Centre Hospitalier Universitaire de Québec- L'Hôtel-dieu de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/hcp/study.aspx?ID=315</url>
    <description>Link to results on the Astellas Clinical Study Results website</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2009</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Advagraf</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Angiotensin-Converting Enzyme Inhibitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

